Lv2
160 积分 2025-01-17 加入
Integrative analysis of RNA modification-related gene PUS7 in diagnosis, prognosis, and tumor microenvironment of hepatocellular carcinoma
11天前
已完结
FRI-079 Prognostic value of early change in neutrophil to lymphocyte ratio after atezolizumab plus bevacizumab treatment for hepatocellular carcinoma
19天前
已完结
Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma
19天前
已完结
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function
19天前
已完结
Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment
19天前
已完结
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
19天前
已完结
Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma
19天前
已完结
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real‐world data
19天前
已完结
Survival of patients with hepatocellular carcinoma treated with immunotherapy experience of a third level center
19天前
已关闭
Comparative efficacy of cabozantinib or lenvatinib following atezolizumab plus bevacizumzb in patients with advanced hepatocellular cancer
19天前
已关闭
皖公网安备34019202002308
